















The Problem	Methods	Results										
<p> In 2020, <b>57,000</b> people died of melanoma</p> <p> <b>Adjuvant immunotherapy</b> has revolutionized resectable melanoma, lowering the risk of recurrence but may result in immune-related adverse events (AE)</p>	<p> Stage III resected melanoma patients completed online surveys (DCE)</p> <p></p> <p> Two alternatives: <b>observation +/- adjuvant immunotherapy</b> presented <b>6 factors</b> (regimen, chance of recurrence, mild, permanent or fatal AE, costs (exclude drug) with <b>2-3 levels</b> varied across 2 options</p> <p> <b>Trade-offs</b> were <b>calculated</b>, and <b>\$\$ willing to pay</b> to avoid risk, e.g. reduction in risk of recurrence</p>	<p><b>116</b>  stage III melanoma <b>53%</b>  Median age <b>60</b></p> <p>Patients' melanoma substage</p> <table border="1"> <tr> <td>III A</td> <td>21%</td> </tr> <tr> <td>III B</td> <td>25%</td> </tr> <tr> <td>III C</td> <td>23%</td> </tr> <tr> <td>III D</td> <td>3%</td> </tr> <tr> <td>Unreported</td> <td>28%</td> </tr> </table> <p> <b>70%</b> prefer adjuvant immunotherapy over no adjuvant immunotherapy</p> <p> More likely to <b>choose immunotherapy</b> if it <b>reduces</b> the chance of <b>recurrence, fatal or permanent AE</b></p> <p> chose immunotherapy less often, odds ratio 0.1, <b>p=0.02</b></p> <p> Patients accepted a 2% increased chance of recurrence to reduce the chance of fatal AE by 1%</p> <p> Those with higher versus lower-income willing to pay US\$595 and US\$1,638 per year for immunotherapy to reduce the 3-yr risk of recurrence by 1%</p>	III A	21%	III B	25%	III C	23%	III D	3%	Unreported	28%
III A	21%											
III B	25%											
III C	23%											
III D	3%											
Unreported	28%											
Purpose												
<p> To quantify <b>stage III resected melanoma</b> patient preferences and trade-offs for adjuvant immunotherapy</p>												

Almost **¾** of stage III resected melanoma patients **chose adjuvant immunotherapy** over no adjuvant immunotherapy

**Women were 90% less likely to choose adjuvant immunotherapy than males**

[ann.livingstone@sydney.edu.au](mailto:ann.livingstone@sydney.edu.au)  [@\\_AnnLiv](https://twitter.com/_AnnLiv)

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® or the author of this poster



**Abstract 9558: Preferences for Adjuvant Immunotherapy in Patients with Resected Stage III Melanoma: A Discrete Choice Experiment (DCE)**



Authors: **Ann Livingstone**<sup>1</sup>, Alexander M Menzies<sup>2,3</sup>, Kirsten Howard<sup>4</sup>, Martin R Stockler<sup>1</sup>, Rachael L Morton<sup>1,2</sup>



<sup>1</sup>NHMRC Clinical Trials Centre, The University of Sydney, Australia; <sup>2</sup>Melanoma Institute Australia, The University of Sydney, Australia; <sup>3</sup>Medical Oncology Department, Royal North Shore and Mater Hospitals, Sydney, Australia; <sup>4</sup>School of Public Health, and the Menzies Centre for Health Policy and Economics, Faculty of Health and Medicine, The University of Sydney, Australia